Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$42.03
+2.3%
$51.28
$36.65
$57.50
$14.83B1.732.29 million shs3.94 million shs
MGM Resorts International stock logo
MGM
MGM Resorts International
$31.03
-0.8%
$34.28
$30.53
$48.24
$8.86B2.185.28 million shs5.26 million shs
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
$1.54
-1.3%
$1.55
$0.60
$4.69
$128.53M1.271.47 million shs2.39 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
+2.34%-8.95%-18.36%-20.80%-10.61%
MGM Resorts International stock logo
MGM
MGM Resorts International
-0.88%-5.50%-9.62%-15.70%-27.49%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Remove Ads

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
4.645 of 5 stars
3.22.02.52.62.72.52.5
MGM Resorts International stock logo
MGM
MGM Resorts International
4.9544 of 5 stars
4.42.01.71.82.73.33.8
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
2.47
Hold$54.9330.70% Upside
MGM Resorts International stock logo
MGM
MGM Resorts International
2.76
Moderate Buy$51.2965.31% Upside
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CG, NGM, and MGM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/24/2025
MGM Resorts International stock logo
MGM
MGM Resorts International
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$39.00 ➝ $41.00
2/14/2025
MGM Resorts International stock logo
MGM
MGM Resorts International
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$50.00
2/13/2025
MGM Resorts International stock logo
MGM
MGM Resorts International
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
2/13/2025
MGM Resorts International stock logo
MGM
MGM Resorts International
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
2/13/2025
MGM Resorts International stock logo
MGM
MGM Resorts International
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
2/13/2025
MGM Resorts International stock logo
MGM
MGM Resorts International
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
2/13/2025
MGM Resorts International stock logo
MGM
MGM Resorts International
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
2/13/2025
MGM Resorts International stock logo
MGM
MGM Resorts International
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
2/13/2025
MGM Resorts International stock logo
MGM
MGM Resorts International
Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$50.00 ➝ $50.00
2/13/2025
MGM Resorts International stock logo
MGM
MGM Resorts International
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$48.00 ➝ $50.00
2/12/2025
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $54.00
(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$3.40B4.46$3.62 per share11.62$17.75 per share2.37
MGM Resorts International stock logo
MGM
MGM Resorts International
$17.24B0.51$4.53 per share6.85$12.90 per share2.41
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
$4.42M29.10N/AN/A$1.80 per share0.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$1.02B$2.7815.128.870.9818.81%24.02%6.53%4/29/2025 (Estimated)
MGM Resorts International stock logo
MGM
MGM Resorts International
$746.56M$2.4012.9310.810.984.33%21.08%1.92%4/29/2025 (Estimated)
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%N/A

Latest CG, NGM, and MGM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/12/2025Q4 2024
MGM Resorts International stock logo
MGM
MGM Resorts International
$0.37$0.45+$0.08$0.52$4.27 billionN/A
2/10/2025Q4 2024
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$1.00$0.92-$0.08$1.27$1.01 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$1.403.33%+11.87%50.36%N/A
MGM Resorts International stock logo
MGM
MGM Resorts International
$0.010.03%N/A0.42%N/A
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/AN/AN/AN/AN/A

Latest CG, NGM, and MGM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
quarterly$0.352.7%2/21/20252/21/20252/28/2025
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
1.42
2.32
2.32
MGM Resorts International stock logo
MGM
MGM Resorts International
1.73
1.30
1.26
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/A
7.79
7.79

Institutional Ownership

CompanyInstitutional Ownership
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
55.88%
MGM Resorts International stock logo
MGM
MGM Resorts International
68.11%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
75.74%

Insider Ownership

CompanyInsider Ownership
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
27.20%
MGM Resorts International stock logo
MGM
MGM Resorts International
2.13%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
35.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
2,200361.20 million260.39 millionOptionable
MGM Resorts International stock logo
MGM
MGM Resorts International
63,000285.55 million279.47 millionOptionable
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
13883.46 million53.50 millionOptionable

Recent News About These Companies

Merck takes stake in NGM amid flurry of pharma deals
cricket win win casino
A venture firm breathes new life into an old NGM drug
Countywide layoffs cool
NGM steps up in Greater Newcastle
Planet Mars, explained
Machu Picchu
What archaeology is telling us about the real Jesus

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
The Carlyle Group stock logo

The Carlyle Group NASDAQ:CG

$42.03 +0.96 (+2.34%)
Closing price 03/12/2025 04:00 PM Eastern
Extended Trading
$41.86 -0.17 (-0.40%)
As of 03/12/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Carlyle Group Inc. is an investment firm specializing in direct and fund of fund investments. Within direct investments, it specializes in management-led/ Leveraged buyouts, privatizations, divestitures, strategic minority equity investments, structured credit, global distressed and corporate opportunities, small and middle market, equity private placements, consolidations and buildups, senior debt, mezzanine and leveraged finance, and venture and growth capital financings, seed/startup, early venture, emerging growth, turnaround, mid venture, late venture, PIPES. The firm invests across four segments which include Corporate Private Equity, Real Assets, Global Market Strategies, and Solutions. The firm typically invests in industrial, agribusiness, ecological sector, fintech, airports, parking, Plastics, Rubber, diversified natural resources, minerals, farming, aerospace, defense, automotive, consumer, retail, industrial, infrastructure, energy, power, healthcare, software, software enabled services, semiconductors, communications infrastructure, financial technology, utilities, gaming, systems and related supply chain, electronic systems, systems, oil and gas, processing facilities, power generation assets, technology, systems, real estate, financial services, transportation, business services, telecommunications, media, and logistics sectors. Within the industrial sector, the firm invests in manufacturing, building products, packaging, chemicals, metals and mining, forestry and paper products, and industrial consumables and services. In consumer and retail sectors, it invests in food and beverage, retail, restaurants, consumer products, domestic consumption, consumer services, personal care products, direct marketing, and education. Within aerospace, defense, business services, and government services sectors, it seeks to invest in defense electronics, manufacturing and services, government contracting and services, information technology, distribution companies. In telecommunication and media sectors, it invests in cable TV, directories, publishing, entertainment and content delivery services, wireless infrastructure/services, fixed line networks, satellite services, broadband and Internet, and infrastructure. Within real estate, the firm invests in office, hotel, industrial, retail, for sale residential, student housing, hospitality, multifamily residential, homebuilding and building products, and senior living sectors. The firm seeks to make investments in growing business including those with overleveraged balance sheets. The firm seeks to hold its investments for four to six years. In the healthcare sector, it invests in healthcare services, outsourcing services, companies running clinical trials for pharmaceutical companies, managed care, pharmaceuticals, pharmaceutical related services, healthcare IT, medical, products, and devices. It seeks to invest in companies based in Sub-Saharan focusing on Ghana, Kenya, Mozambique, Botswana, Nigeria, Uganda, West Africa, North Africa and South Africa focusing on Tanzania and Zambia; Asia focusing on Pakistan, India, South East Asia, Indonesia, Philippines, Vietnam, Korea, and Japan; Australia; New Zealand; Europe focusing on France, Italy, Denmark, United Kingdom, Germany, Austria, Belgium, Finland, Iceland, Ireland, Netherlands, Norway, Portugal, Spain, Benelux , Sweden, Switzerland, Hungary, Poland, and Russia; Middle East focusing on Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey, and UAE; North America focusing on United States which further invest in Southeastern United States, Texas, Boston, San Francisco Bay Area and Pacific Northwest; Asia Pacific; Soviet Union, Central-Eastern Europe, and Israel; Nordic region; and South America focusing on Mexico, Argentina, Brazil, Chile, and Peru. The firm seeks to invest in food, financial, and healthcare industries in Western China. In the real estate sector, the firm seeks to invest in various locations across Europe focusing on France and Central Europe, United States, Asia focusing on China, and Latin America. It typically invests between $1 million and $50 million for venture investments and between $50 million and $2 billion for buyouts in companies with enterprise value of between $31.57 million and $1000 million and sales value of $10 million and $500 million. It seeks to invest in companies with market capitalization greater than $50 million and EBITDA between $5 million to $25 million. It prefers to take a majority or a minority stake. While investing in Japan, it does not invest in companies with more than 1,000 employees and prefers companies' worth between $100 million and $150 million. The firm originates, structures, and acts as lead equity investor in the transactions. The Carlyle Group Inc. was founded in 1987 and is based in Washington, District of Columbia with additional offices in 21 countries across 5 continents (North America, South America, Asia, Australia and Europe).

MGM Resorts International stock logo

MGM Resorts International NYSE:MGM

$31.03 -0.26 (-0.83%)
Closing price 03/12/2025 03:58 PM Eastern
Extended Trading
$31.30 +0.28 (+0.89%)
As of 03/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MGM Resorts International, through its subsidiaries, owns and operates casino, hotel, and entertainment resorts in the United States and internationally. The company operates through three segments: Las Vegas Strip Resorts, Regional Operations, and MGM China. Its casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. The company's casino operations include slots and table games, as well as online sports betting and iGaming through BetMGM. Its customers include premium gaming customers; leisure and wholesale travel customers; business travelers; and group customers, including conventions, trade associations, and small meetings. The company was formerly known as MGM MIRAGE and changed its name to MGM Resorts International in June 2010. MGM Resorts International was incorporated in 1986 and is based in Las Vegas, Nevada.

NGM Biopharmaceuticals stock logo

NGM Biopharmaceuticals NASDAQ:NGM

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.